IMUNON INC (IMNN) Stock Price, Quote, News and Overview
NASDAQ:IMNN - Nasdaq - US15117N6022 - Common Stock - Currency: USD
IMNN Quote, Performance and Key Statistics
0.919
+0.05 (+5.39%)
The current stock price of IMNN is 0.919 USD. In the past month the price decreased by -4.02%. In the past year, price increased by 56.03%.
IMNN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About IMNN
Company Profile
Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 33 full-time employees. The firm is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The firm is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.
Company Info
IMUNON INC
997 Lenox Dr Ste 100
Lawrenceville NEW JERSEY US
Employees: 33
Company Website: https://imunon.com/
Investor Relations: https://investors.imunon.com/
Phone: 16098969100
IMUNON INC / IMNN FAQ
What is the stock price of IMUNON INC today?
The current stock price of IMNN is 0.919 USD. The price increased by 5.39% in the last trading session.
What is the ticker symbol for IMUNON INC stock?
The exchange symbol of IMUNON INC is IMNN and it is listed on the Nasdaq exchange.
On which exchange is IMNN stock listed?
IMNN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMUNON INC stock?
10 analysts have analysed IMNN and the average price target is 13.46 USD. This implies a price increase of 1365.07% is expected in the next year compared to the current price of 0.919. Check the IMUNON INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMUNON INC worth?
IMUNON INC (IMNN) has a market capitalization of 13.33M USD. This makes IMNN a Nano Cap stock.
How many employees does IMUNON INC have?
IMUNON INC (IMNN) currently has 33 employees.
What are the support and resistance levels for IMUNON INC (IMNN) stock?
IMUNON INC (IMNN) has a support level at 0.91 and a resistance level at 0.93. Check the full technical report for a detailed analysis of IMNN support and resistance levels.
Should I buy IMUNON INC (IMNN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMNN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMNN, evaluating the profitability, health, valuation and growth aspects
- IMUNON INC (IMNN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMUNON INC (IMNN) Sales and EPS estimates to see what analysts future expectations are.
- IMUNON INC (IMNN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMUNON INC (IMNN) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMUNON INC (IMNN) Stock Chart to make your own analysis
- IMUNON INC (IMNN) Latest news and press-releases to stay up to date.
Does IMUNON INC (IMNN) stock pay dividends?
IMNN does not pay a dividend.
When does IMUNON INC (IMNN) report earnings?
IMUNON INC (IMNN) will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of IMUNON INC (IMNN)?
IMUNON INC (IMNN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.89).
What is the Short Interest ratio of IMUNON INC (IMNN) stock?
The outstanding short interest for IMUNON INC (IMNN) is 7.51% of its float. Check the ownership tab for more information on the IMNN short interest.
IMNN Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to IMNN. When comparing the yearly performance of all stocks, IMNN is one of the better performing stocks in the market, outperforming 91.71% of all stocks.
IMNN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMNN. While IMNN seems to be doing ok healthwise, there are quite some concerns on its profitability.
IMNN Financial Highlights
Over the last trailing twelve months IMNN reported a non-GAAP Earnings per Share(EPS) of -1.89. The EPS increased by 42.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -186.58% | ||
| ROE | -483.32% | ||
| Debt/Equity | 0 |
IMNN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to IMNN. The Buy consensus is the average rating of analysts ratings from 10 analysts.